




Peter Greenberg

Professor of Medicine (Hematology), Emeritus

Medicine - Hematology

 Curriculum Vitae available Online

CLINICAL OFFICES

- **Hematology Clinic**

875 Blake Wilbur Dr Clinic C

MC 5820

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 498-5030

Bio

BIO

As Director of the Stanford MDS Center, Dr Greenberg has an active clinical practice focusing on myelodysplastic syndromes (MDS) and clonal myeloid disorders. His clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and is now evaluating the impact of molecular mutations on this risk-based prognostic system. He is Chair of the NCCN Practice Guidelines Panel for MDS.

CLINICAL FOCUS

- Cancer > Hematology
- Hematology
- Myelodysplastic Syndromes

ACADEMIC APPOINTMENTS

- Professor Emeritus, Medicine - Hematology
- Member, Bio-X
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Acting Chief, Medical Service, VA Palo Alto Health Care System, (1978-1979)
- Head, Hematology Section, VA Palo Alto Health Care System, (1979-2005)
- Director, Stanford MDS Center, (1998-2016)
- Chair, National Comprehensive Cancer Network Myelodysplastic Syndromes Practice Guidelines Panel, (1997-2016)
- Coordinator, International Working Group for Prognosis in MDS, (2009-2016)

HONORS AND AWARDS

- International Prize for outstanding research in myelodysplastic syndromes (MDS), J.P. McCarthy Foundation (1997)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Society of Hematology (1972 - present)
- Member, Eastern Cooperative Oncology Group, Leukemia Committee (1993 - present)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University School of Medicine Registrar (1971) CA
- Residency: Stanford University School of Medicine Registrar (1968) CA
- Residency: Barnes Hospital (1965) MO
- Board Certification: Hematology, American Board of Internal Medicine (1976)
- Board Certification: Internal Medicine, American Board of Internal Medicine (1970)
- Internship: Barnes Hospital (1964) MO
- B.A., Johns Hopkins University , Biological Sciences (1959)
- M.D., George Washington U Med School , Medicine (1963)

COMMUNITY AND INTERNATIONAL WORK

- Chair, ASH Committee on International Outreach, 1998-2001

LINKS

- <http://hematology.stanford.edu/>: <http://hematology.stanford.edu/>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

The major direction of research in my laboratory is to determine the role and mechanisms of hemopoietic dysregulation in human myeloid malignancies. The relation between molecular changes and cellular phenotype / pathophysiology is being explored using microarray and next generation technologies to evaluate differential gene expression profiles of MDS and AML marrow cells. The impact of cytokines and biologic response modifiers on these molecular features and hemopoietic response is being examined in clinical investigations with MDS and AML patients in therapeutic clinical trials with these agents.

CLINICAL TRIALS

- A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia, Recruiting
- A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes, Not Recruiting
- A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes, Not Recruiting
- A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia, Not Recruiting
- Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia, Not Recruiting
- Bevacizumab in Treating Patients With Myelodysplastic Syndrome, Not Recruiting
- Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine, Not Recruiting
- Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk, Not Recruiting
- Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk, Not Recruiting

- Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs, Not Recruiting
- Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk, Not Recruiting
- Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL, Not Recruiting
- Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF), Not Recruiting
- Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders, Not Recruiting
- Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders, Not Recruiting

Publications

PUBLICATIONS

- **Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance** *GENES CHROMOSOMES & CANCER*
Schanz, J., Sole, F., Mallo, M., Luno, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., Fonatsch, C., Pfeilstoecker, M., Noesslinger, T., Valent, et al
2018; 57 (11): 547–56
- **Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy.** *Blood advances*
Aleshin, A., Greenberg, P. L.
2018; 2 (20): 2787–97
- **Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS** *LEUKEMIA RESEARCH*
Miyazaki, Y., Tuechler, H., Sanz, G., Schanz, J., Garcia-Manero, G., Sole, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Malcovati, et al
2018; 73: 51–57
- **Distinct Transcriptomic and Exomic Abnormalities Within Myelodysplastic Syndrome Marrow Cells** *Leukemia & Lymphoma*
Im, H., Rao, V., Sridhar, K., Bentley, J., Mishra, T., Chen, R., Hall, J., Graber, A., Zhang, Y., Xiao, L., Mias, G., Snyder, M. P., Greenberg, et al
2018: 1-11
- **Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions** *ONCOTARGET*
Valent, P., Orazi, A., Steensma, D. P., Ebert, B. L., Haase, D., Malcovati, L., van de Loosdrecht, A. A., Haferlach, T., Westers, T. M., Wells, D. A., Giagounidis, A., Loken, M., Orfao, et al
2017; 8 (43): 73483–500
- **CHROMOSOMAL ABERRATIONS IN THERAPY-RELATED MYELODYSPLASTIC SYNDROMES - RELATIONS TO PRIMARY DISEASE, THERAPY AND PROGNOSTIC SIGNIFICANCE**
Nomdedeu, M., Tuechler, H., Kuendgen, A., Sole, F., Schanz, J., Hildebrandt, B., Grau, J., Pereira, A., Garcia-Manero, G., Sekeres, M. A., Komrokji, R. S., Voso, M. T., List, et al
PERGAMON-ELSEVIER SCIENCE LTD.2017: S32–S33
- **Myelodysplastic Syndromes, Practice Guidelines, Version 2.2017** *J Nat Compr Canc Netw*
Greenberg, P. L., Stone, R., Al Kali, A., et al
2017; 15: 60-87
- **The Classical Nature of Distinctive CMML Monocytes** *Blood*
Greenberg, P. L.
2017; 129: 1745-1746
- **Myelodysplastic Syndromes, Version 2.2017 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Greenberg, P. L., Stone, R. M., Al-Kali, A., Barta, S. K., Bejar, R., Bennett, J. M., Carraway, H., De Castro, C. M., Deeg, H. J., DeZern, A. E., Fathi, A. T., Frankfurt, O., Gaensler, et al
2017; 15 (1): 60-87
- **The Impact of Somatic and Germline Mutations in MDS and Related Disorders** *J Nat Comp Canc Network*

- Bejar, R., Greenberg, P. L.
2017; 15: 137-141
- **KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.** *Leukemia research*
Swords, R. T., Greenberg, P. L., Wei, A. H., Durrant, S., Advani, A. S., Hertzberg, M. S., Lewis, I. D., Rivera, G., Gratzinger, D., Fan, A. C., Felsher, D. W., Cortes, J. E., Watts, et al
2016; 50: 123-131
 - **Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis** *BRITISH JOURNAL OF HAEMATOLOGY*
Park, S., Fenaux, P., Greenberg, P., Mehta, B., Callaghan, F., Kim, C., Tomita, D., Xu, H.
2016; 174 (5): 730-747
 - **Time-dependent changes in mortality and transformation risk in MDS.** *Blood*
Pfeilstöcker, M., Tuechler, H., Sanz, G., Schanz, J., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Malcovati, et al
2016; 128 (7): 902-910
 - **Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.** *Blood*
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, et al
2016
 - **Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial** *LANCET ONCOLOGY*
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., Gaidano, G., Scott, B. L., Greenberg, P., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, et al
2016; 17 (4): 496-508
 - **Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome** *LEUKEMIA & LYMPHOMA*
Narayan, R., Garcia, J. S., Percival, M. M., Berube, C., Coutre, S., Gotlib, J., Greenberg, P., Liedtke, M., Hewitt, R., Regan, K., Williamson, C., Doykan, C., Cardone, et al
2016; 57 (3): 609-615
 - **The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.** *Clinical cancer research*
Maxson, J. E., Luty, S. B., Macmaniman, J. D., Paik, J. C., Gotlib, J., Greenberg, P., Bahamadi, S., Savage, S. L., Abel, M. L., Eide, C. A., Loriaux, M. M., Stevens, E. A., Tyner, et al
2016; 22 (3): 757-764
 - **Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.** *British journal of haematology*
Prebet, T., Sun, Z., Ketterling, R. P., Zeidan, A., Greenberg, P., Herman, J., Juckett, M., Smith, M. R., Malick, L., Paietta, E., Czader, M., Figueroa, M., Gabrilove, et al
2016; 172 (3): 384-391
 - **Immune checkpoint pathways: perspectives on myeloid malignancies** *LEUKEMIA & LYMPHOMA*
Rivera, G. A., Behbahan, I. S., Greenberg, P. L.
2016; 57 (5): 995-1001
 - **Cytopenia Levels for Aiding Establishment of the Diagnosis of Myelodysplastic Syndromes** *Blood*
Greenberg, P. L., Tuechler, H., et al
2016; 128 (16): 2096
 - **Frequency of del(12p) is Commonly Underestimated in Myelodysplastic Syndromes: Results from a German Diagnostic Study in Comparison with an International Control Group** *GENES CHROMOSOMES & CANCER*
Braulke, F., Mueller-Thomas, C., Goetze, K., Platzbecker, U., Germing, U., Hofmann, W., Giagounidis, A. A., Luebbert, M., Greenberg, P. L., Bennett, J. M., Sole, F., Slovak, M. L., Ohyashiki, et al
2015; 54 (12): 809-817

- **Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial** *LANCET HAEMATOLOGY*
Platzbecker, U., Wong, R. S., Verma, A., Abboud, C., Araujo, S., Chiou, T., Feigert, J., Yeh, S., Goetze, K., Gorin, N., Greenberg, P., Kambhampati, S., Kim, et al
2015; 2 (10): E417-E426
- **Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).** *Leukemia*
Della Porta, M. G., Tuechler, H., Malcovati, L., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, et al
2015; 29 (7): 1502-1513
- **Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy** *HEMATOLOGICAL ONCOLOGY*
Silverman, L. R., Greenberg, P., Raza, A., Olnes, M. J., Holland, J. F., Reddy, P., Maniar, M., Wilhelm, F.
2015; 33 (2): 57-66
- **MDS prognostic scoring systems - Past, present, and future** *BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY*
Jonas, B. A., Greenberg, P. L.
2015; 28 (1): 3-13
- **Myelodysplastic Syndromes, Version 2.2015** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Greenberg, P. L., Stone, R. M., Bejar, R., Bennett, J. M., Bloomfield, C. D., Borate, U., De Castro, C. M., Deeg, H. J., DeZern, A. E., Fathi, A. T., Frankfurt, O., Gaensler, K., Garcia-Manero, et al
2015; 13 (3): 261-272
- **Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34(+)FISH: results from a German diagnostic study in comparison with an international control group** *HAEMATOLOGICA*
Braulke, F., Platzbecker, U., Mueller-Thomas, C., Goetze, K., Germing, U., Bruemmendorf, T. H., Nolte, F., Hofmann, W., Giagounidis, A. A., Luebbert, M., Greenberg, P. L., Bennett, J. M., Sole, et al
2015; 100 (2): 205-213
- **Synergistic Interactions of Molecular and Clinical Advances for Characterizing the Myelodysplastic Syndromes** *J Nat Compr Canc Network*
Greenberg, P. L.
2015; 13 (7): 829-832
- **Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival.** *American journal of clinical pathology*
Johnson, R. C., Kurzer, J. H., Greenberg, P. L., Gratzinger, D.
2014; 142 (6): 795-802
- **Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS** *BRITISH JOURNAL OF HAEMATOLOGY*
Zeidan, A. M., Lee, J., Prebet, T., Greenberg, P., Sun, Z., Juckett, M., Smith, M. R., Paietta, E., Gabrilove, J., Erba, H. P., Katterling, R. P., Tallman, M. S., Gore, et al
2014; 167 (1): 62-68
- **Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes** *BRITISH JOURNAL OF HAEMATOLOGY*
Zeidan, A. M., Lee, J., Prebet, T., Greenberg, P., Sun, Z., Juckett, M., Smith, M. R., Paietta, E., Gabrilove, J., Erba, H. P., Tallman, M. S., Gore, S. D.
2014; 166 (3): 352-359
- **Prolonged Administration of Azacitidine With or Without Eentinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905** *JOURNAL OF CLINICAL ONCOLOGY*
Prebet, T., Sun, Z., Figueroa, M. E., Ketterling, R., Melnick, A., Greenberg, P. L., Herman, J., Juckett, M., Smith, M. R., Malick, L., Paietta, E., Czader, M., Litzow, et al
2014; 32 (12): 1242-?
- **Mesenchymal Stromal Cell Density is Increased in Higher Grade Myelodysplastic Syndromes and Independently Predicts Survival.** *J Clin Path*
Johnson, R., Kurzer, J., Greenberg, P., Gratzinger, D.
2014; 142: 795-802

- **Update on Myelodysplastic Syndromes Classification and Prognosis.** *Surgical pathology clinics*
Gratzinger, D., Greenberg, P. L.
2013; 6 (4): 693-728
- **Monosomal karyotype in MDS: explaining the poor prognosis?** *LEUKEMIA*
Schanz, J., Tuechler, H., Sole, F., Mallo, M., Luno, E., Cervera, J., Grau, J., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstoecker, et al
2013; 27 (10): 1988-1995
- **Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.** *Journal of clinical oncology*
Koreth, J., Pidala, J., Perez, W. S., Deeg, H. J., Garcia-Manero, G., Malcovati, L., Cazzola, M., Park, S., Itzykson, R., AdeS, L., Fenaux, P., Jadersten, M., Hellstrom-Lindberg, et al
2013; 31 (21): 2662-2670
- **The Multifaceted Nature of Myelodysplastic Syndromes: Clinical, Molecular, and Biological Prognostic Features** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Greenberg, P. L.
2013; 11 (7): 877-885
- **Myelodysplastic syndromes: clinical practice guidelines in oncology.** *Journal of the National Comprehensive Cancer Network*
Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., Borate, U., De Castro, C. M., Deeg, H. J., Frankfurt, O., Gaensler, K., Garcia-Manero, G., Gore, S. D., Head, D., Komrokji, et al
2013; 11 (7): 838-874
- **Myelodysplastic Syndromes** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., Borate, U., De Castro, C. M., Deeg, H. J., Frankfurt, O., Gaensler, K., Garcia-Manero, G., Gore, S. D., Head, D., Komrokji, et al
2013; 11 (7): 838-874
- **Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.** *Haematologica*
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., Greenberg, P., Zhang, B., Liedtke, M., Berube, C., Levine, R., Mitchell, B. S., Medeiros, et al
2013; 98 (4): 591-596
- **Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Pang, W. W., Pluvinae, J. V., Price, E. A., Sridhar, K., Arber, D. A., Greenberg, P. L., Schrier, S. L., Park, C. Y., Weissman, I. L.
2013; 110 (8): 3011-3016
- **Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials** *JOURNAL OF CLINICAL ONCOLOGY*
Koontz, M. Z., Horning, S. J., Balise, R., Greenberg, P. L., Rosenberg, S. A., Hoppe, R. T., Advani, R. H.
2013; 31 (5): 592-598
- **A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine** *LEUKEMIA & LYMPHOMA*
Greenberg, P. L., Garcia-Manero, G., Moore, M., Damon, L., Roboz, G., Hu, K., Yang, A. S., Franklin, J.
2013; 54 (2): 321-328
- **Specific plasma autoantibody reactivity in myelodysplastic syndromes** *Scientific Reports*
Mias, G. I., Chen, R., Zhang, Y., Sridhar, K., Sharon, D., Xiao, L., Im, H., Snyder, M. P., Greenberg, P. L.
2013; 3: 3311-3319
- **Reduced rRNA expression and increased rDNA promoter methylation in CD34(+) cells of patients with myelodysplastic syndromes** *BLOOD*
Raval, A., Sridhar, K. J., Patel, S., Turnbull, B. B., Greenberg, P. L., Mitchell, B. S.
2012; 120 (24): 4812-4818
- **Revised International Prognostic Scoring System for Myelodysplastic Syndromes** *BLOOD*
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, et al

2012; 120 (12): 2454-2465

- **Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow** *LABORATORY INVESTIGATION*
Flores-Figueroa, E., Varma, S., Montgomery, K., Greenberg, P. L., Grattinger, D.
2012; 92 (9): 1330-1341
- **Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS** *BLOOD*
Barreyro, L., Will, B., Bartholdy, B., Zhou, L., Todorova, T. I., Stanley, R. F., Ben-Neriah, S., Montagna, C., Parekh, S., Pellagatti, A., Boulwood, J., Paietta, E., Ketterling, et al
2012; 120 (6): 1290-1298
- **Molecular and genetic features of myelodysplastic syndromes** *INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY*
Greenberg, P. L.
2012; 34 (3): 215-222
- **Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes** *CELL*
Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Y., Chen, R., Miriami, E., Karczewski, K. J., Hariharan, M., Dewey, F. E., Cheng, Y., Clark, M. J., Im, et al
2012; 148 (6): 1293-1307
- **New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge** *JOURNAL OF CLINICAL ONCOLOGY*
Schanz, J., Tuechler, H., Sole, F., Mallo, M., Luno, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstoeker, et al
2012; 30 (8): 820-829
- **Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow** *Lab Investigation*
Flores-Figueroa E, Varma S, Montgomery K, Greenberg P, Grattinger D
2012; 92: 1330-1341
- **Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na** *LEUKEMIA RESEARCH*
Seetharam, M., Fan, A. C., Tran, M., Xu, L., Renschler, J. P., Felsher, D. W., Sridhar, K., Wilhelm, F., Greenberg, P. L.
2012; 36 (1): 98-103
- **A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib)** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Fan, A. C., Xu, L., Sridhar, K. J., Tran, M., Banerjee, P., Renschler, J. P., Tripuraneni, R., Wilhelm, F., Greenberg, P. L., Felsher, D. W.
AMER SOC HEMATOLOGY.2011: 1626-26
- **Myelodysplastic Syndromes: Dissecting the Heterogeneity** *JOURNAL OF CLINICAL ONCOLOGY*
Greenberg, P. L.
2011; 29 (15): 1937-1938
- **NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.** *Journal of the National Comprehensive Cancer Network*
Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., Foran, J. M., Gaensler, K., Garcia-Manero, G., Gore, S. D., Head, D., Komrokji, R., Maness, et al
2011; 9 (1): 30-56
- **Myelodysplastic Syndromes** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., Foran, J. M., Gaensler, K., Garcia-Manero, G., Gore, S. D., Head, D., Komrokji, R., Maness, et al
2011; 9 (1): 30-56
- **Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes** *LEUKEMIA RESEARCH*
Greenberg, P. L., Koller, C. A., Cabantchik, Z. I., Warsi, G., Glynos, T., Paley, C., Schiffer, C.
2010; 34 (12): 1560-1565
- **Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy** *BLOOD*
Kantarjian, H. M., Giles, F. J., Greenberg, P. L., Paquette, R. L., Wang, E. S., Gabrielove, J. L., Garcia-Manero, G., Hu, K., Franklin, J. L., Berger, D. P.

2010; 116 (17): 3163-3170

- **Current therapeutic approaches for patients with myelodysplastic syndromes** *BRITISH JOURNAL OF HAEMATOLOGY*
Greenberg, P. L.
2010; 150 (2): 131-143
- **NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes.** *Journal of the National Comprehensive Cancer Network*
Greenberg, P. L., Rigsby, C. K., Stone, R. M., Deeg, H. J., Gore, S. D., Millenson, M. M., Nimer, S. D., O'Donnell, M. R., Shami, P. J., Kumar, R.
2009; 7: S1-16
- **Relationship of differential gene expression profiles in CD34(+) myelodysplastic syndrome marrow cells to disease subtype and progression** *BLOOD*
Sridhar, K., Ross, D. T., Tibshirani, R., Butte, A. J., Greenberg, P. L.
2009; 114 (23): 4847-4858
- **Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)** *BLOOD*
Greenberg, P. L., Sun, Z., Miller, K. B., Bennett, J. M., Tallman, M. S., Dewald, G., Paietta, E., van der Jagt, R., Houston, J., Thomas, M. L., Cella, D., Rowe, J. M.
2009; 114 (12): 2393-2400
- **A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes** *AMERICAN JOURNAL OF HEMATOLOGY*
Gotlib, J., Lavori, P., Quesada, S., Stein, R. S., Shahnia, S., Greenberg, P. L.
2009; 84 (1): 15-20
- **NCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes** *J Nat Comp Cancer Network*
Greenberg, P., Rigsby C, Stone RM, Deeg J, Gore S, Millenson M, Nimer S, O'Donnell M, Shami P, Kumar R
2009; 7 ((Suppl 9): S1-16
- **Myelodysplastic syndromes.** *Journal of the National Comprehensive Cancer Network*
Greenberg, P. L., Attar, E., Battiwalla, M., Bennett, J. M., Bloomfield, C. D., DeCastro, C. M., Deeg, H. J., Erba, H. P., Foran, J. M., Garcia-Manero, G., Gore, S. D., Head, D., Maness, et al
2008; 6 (9): 902-926
- **The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.** *Journal of the National Comprehensive Cancer Network*
Greenberg, P. L., Cosler, L. E., Ferro, S. A., Lyman, G. H.
2008; 6 (9): 942-953
- **Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy** *JOURNAL OF CLINICAL ONCOLOGY*
Sloand, E. M., Wu, C. O., Greenberg, P., Young, N., Barrett, J.
2008; 26 (15): 2505-2511
- **A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia** *BLOOD*
Raponi, M., Lancet, J. E., Fan, H., Dossey, L., Lee, G., Gojo, I., Feldman, E. J., Gotlib, J., Morris, L. E., Greenberg, P. L., Wright, J. J., Harousseau, J., Loewenberg, et al
2008; 111 (5): 2589-2596
- **Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study** *EUROPEAN JOURNAL OF HAEMATOLOGY*
Porter, J., Galanello, R., Saglio, G., Neufeld, E. J., Vichinsky, E., Cappellini, M. D., Olivieri, N., Piga, A., Cunningham, M. J., Soulieres, D., Gattermann, N., Tchernia, G., Maertens, et al
2008; 80 (2): 168-176
- **Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience** *BLOOD*
Park, S., Grabar, S., Kelaidi, C., Beyne-Rauzy, O., Picard, F., Bardet, V., Coiteux, V., Leroux, G., Lepelley, P., Daniel, M., Cheze, S., Mahe, B., Ferrant, et al
2008; 111 (2): 574-582
- **International MDS Risk Analysis Workshop (IMRAW)/IPSS Re-analyzed: Impact of cytopenias on clinical outcomes in Myelodysplastic Syndrome** *Am J Hematology*
Kao, J. M., McMillan, A., Greenberg, P. L.
2008; 83: 765-770

- **Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q** *48th Annual Meeting of the American-Society-of-Hematology*
Raza, A., Reeves, J. A., Feldman, E. J., Dewald, G. W., Bennett, J. M., Deeg, J., Dreisbach, L., Schiffer, C. A., Stone, R. M., Greenberg, P. L., Curtin, P. T., Klimek, V. M., Shammo, et al
AMER SOC HEMATOLOGY.2008: 86-93
- **Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF** *Blood*
Park S, Grabar S, Kelaidi C, Greenberg P, et al.
2008; 111: 574-582
- **Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-year prospective study.** *Eur J Haematol*
Porter J, Galanello R, Saglio S, Greenberg P, et al
2008; 80: 168-176
- **Phase II Study of Lenalidomide in Transfusion-Dependent, Low and Intermediate-1-Risk Myelodysplastic Syndromes with Normal and Abnormal Karyotypes Other than Deletion 5q.** *Blood*
Raza A, Reeves JE, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, et al
2008; 111: 86-93
- **Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference** *LEUKEMIA RESEARCH*
Valent, P., Horny, H., Bennett, J. M., Fonatsch, C., Germing, U., Greenberg, P., Haferlach, T., Haase, D., Kolb, H., Krieger, O., Loken, M., van de Loosdrecht, A., Ogata, et al
2007; 31 (6): 727-736
- **Chronic myelogenous leukemia.** *Journal of the National Comprehensive Cancer Network*
O'Brien, S., Berman, E., Bhalla, K., Copelan, E. A., Devetten, M. P., Emanuel, P. D., Erba, H. P., Greenberg, P. L., Moore, J. O., Przepiorka, D., Radich, J. P., Schilder, R. J., Shami, et al
2007; 5 (5): 474-496
- **A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia** *BLOOD*
Lancet, J. E., Gojo, I., Gotlib, J., Feldman, E. J., Greer, J., Liesveld, J. L., Bruzek, L. M., Morris, L., Park, Y., Adjei, A. A., Kaufmann, S. H., Garrett-Mayer, E., Greenberg, et al
2007; 109 (4): 1387-1394
- **Myelodysplastic Syndromes: Impact of recently analyzed variables for modifying current classification methods** *Clinical Leukemia*
Kao JM, Greenberg PL
2007; 1: 172-182
- **Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus Statements and Report from a Working Conference** *Leukemia Research*
Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al
2007; 31: 727-736
- **Phase I/II, randomized, MultiCenter, dose-ascension study of the p38MAPK inhibitor scio469 in patients with myelodysplastic syndrome (MDS).** *48th Annual Meeting of the American-Society-of-Hematology*
Sokol, L., Cripe, L., Kantarjian, H., Sekeres, M. A., Parmar, S., Greenberg, P., Goldberg, S., Bhushan, V., Shammo, J., Hohl, R., Li, Y., Lowe, A., Zhu, et al
AMER SOC HEMATOLOGY.2006: 751A-751A
- **Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion** *NEW ENGLAND JOURNAL OF MEDICINE*
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., Reeder, C., Wride, K., Patin, et al
2006; 355 (14): 1456-1465
- **Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia** *BLOOD*
Cheson, B. D., Greenberg, P. L., Bennett, J. M., Lowenberg, B., Wijermans, P. W., Nimer, S. D., Pinto, A., Beran, M., de Witte, T. M., Stone, R. M., Mittelman, M., Sanz, G. F., Gore, et al
2006; 108 (2): 419-425
- **Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q deletion.** *New Eng J Med*

- List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, et al
2006; 355: 1456-1465
- **Myelodysplastic syndromes clinical practice guidelines in oncology.** *Journal of the National Comprehensive Cancer Network*
Greenberg, P. L., Baer, M. R., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., Devetten, M. P., Emanuel, P. D., Erba, H. P., Estey, E., Foran, J., Gore, S. D., Millenson, et al
2006; 4 (1): 58-77
 - **A phase II study of the farnesyltransferase inhibitor tipifarnib in elderly patients with previously untreated poor-risk acute myeloid leukemia** *Blood*
Lancet J, Gojo I, Gotlib J, Greenberg PL, et al
2006; 108: 1387-1394
 - **Myelodysplastic Syndromes: Clinical and Biological Advances** *Cambridge University Press, Cambridge, England*
Greenberg, P. L.
2006
 - **Myelodysplastic syndromes: iron overload consequences and current chelating therapies.** *Journal of the National Comprehensive Cancer Network*
Greenberg, P. L.
2006; 4 (1): 91-96
 - **Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.** *Blood*
Cheson BD, Greenberg PL, Bennett JM, et al
2006; 108: 419-425
 - **Management of patients with higher risk myelodysplastic syndromes** *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY*
Fukumoto, J. S., Greenberg, P. L.
2005; 56 (2): 179-192
 - **Chronic myelogenous leukemia.** *Journal of the National Comprehensive Cancer Network*
O'Brien, S., Berman, E., Bhalla, K., Copelan, E. A., Devetten, M. P., Emanuel, P. D., Erba, H. P., Greenberg, P. L., Moore, J. O., Przepiorka, D., Radich, J. P., Schilder, R. J., Shami, et al
2005; 3 (6): 732-755
 - **A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome** *BLOOD*
Cutler, C. S., Lee, S. J., Greenberg, P., Deeg, H. J., Perez, W. S., Anasetti, C., Bolwell, B. J., Cairo, M. S., Gale, R. P., Klein, J. P., Lazarus, H. M., Liesveld, J. L., McCarthy, et al
2004; 104 (2): 579-585
 - **Mitoxantrone, etoposide, and cytarabine with or without valsopodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)** *JOURNAL OF CLINICAL ONCOLOGY*
Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., Letendre, L., Dugan, K., Lum, B., Chin, D. L., Dewald, G., Paietta, E., Bennett, J. M., Rowe, et al
2004; 22 (6): 1078-1086
 - **A Decision Analysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes: Delayed Transplantation for Low Risk Myelodysplasia is Associated with Improved Outcome** *Blood*
Cutler C, Lee SJ, Greenberg P, et al
2004; 104: 579-585
 - **Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study** *LEUKEMIA RESEARCH*
Chery, A. M., Brockman, S. R., Paternoster, S. F., Hicks, G. A., Neuberg, D., Higgins, R. R., Bennett, J. M., Greenberg, P. L., Miller, K., Tallman, M. S., Rowe, J., DeWald, G. W.
2003; 27 (12): 1085-1090
 - **Phase II study of Bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS): Preliminary results** *45th Annual Meeting and Exhibition of the American-Society-of-Hematology*
Gotlib, J., Jamieson, C. H., List, A., Cortes, J., Albitar, M., Sridhar, K., Dugan, K., Quesada, S., Diaz, G., Pate, O., Novotny, W., Chen, H., Greenberg, et al
AMER SOC HEMATOLOGY.2003: 425A-425A

- **Novel biospecific agents for the treatment of myelodysplastic syndromes.** *J Nat Comprehensive Cancer Network*
Gotlib J, Greenberg P
2003; 1: 473-480
- **Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study** *LEUKEMIA*
Deeg, H. J., Gotlib, J., Beckham, C., Dugan, K., Holmberg, L., Schubert, M., Appelbaum, F., Greenberg, P.
2002; 16 (2): 162-164
- **Myelodysplastic syndromes.** *Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program*
Greenberg, P. L., Young, N. S., Gattermann, N.
2002: 136-161
- **Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines** *ANNALS OF THE RHEUMATIC DISEASES*
Greenberg, P.
2001; 60: III41-III42
- **Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes** *LANCET*
Greenberg, P.
2001; 357 (9262): 1059-1060
- **NCCN Practice Guidelines for chronic myelogenous leukemia** *ONCOLOGY-NEW YORK*
Talpa, M., Berman, E., Clift, R. A., Copelan, E. A., Emanuel, P. D., Erba, H. P., Glenn, M. J., Greenberg, P. L., Jones, R. J., O'Brien, S., Saba, H. I., Schilder, R., Snyder, et al
2000; 14 (11A): 229-240
- **The Myelodysplastic Syndromes .** *HEMATOLOGY: BASIC PRINCIPLES AND PRACTICE 3rd Ed., Hoffman R, Benz E, Shattil S, Furie B, Cohen H, Silberstein L, McGlave P, Eds. Churchill Livingstone, NY,*
Greenberg, P.
2000: 1106-1129
- **Prognostic scoring systems for risk assessment in myelodysplastic syndromes.** *Forum (Genoa, Italy)*
Greenberg, P. L., Sanz, G. F., Sanz, M. A.
1999; 9 (1): 17-31
- **Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment** *LEUKEMIA RESEARCH*
Greenberg, P. L.
1998; 22 (12): 1123-1136
- **Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression** *36th Annual Meeting of the American-Society-of-Hematology*
Davis, R. E., Greenberg, P. L.
PERGAMON-ELSEVIER SCIENCE LTD.1998: 767-77
- **Risk factors and their relationship to prognosis in myelodysplastic syndromes** *LEUKEMIA RESEARCH*
Greenberg, P. L.
1998; 22: S3-S6
- **Prognostic factors and scoring systems in myelodysplastic syndromes** *HAEMATOLOGICA*
Sanz, G. F., Sanz, M. A., Greenberg, P. L.
1998; 83 (4): 358-368
- **NCCN Practice Guidelines for Myelodysplastic Syndromes** *Oncology*
Greenberg PL, Bishop M, Deeg J, Erba H, Gore S, Nimer S, ODonnell M, Tallman M, Bennett J, Estey E, Stone R
1998; 12 (11A): 53-80
- **Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model** *BRITISH JOURNAL OF HAEMATOLOGY*
HELLSTROMLINDBERG, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G., Vardiman, J., Ost, A., Greenberg, P.
1997; 99 (2): 344-351

- **International scoring system for evaluating prognosis in myelodysplastic syndromes** *BLOOD*
Greenberg, P., Cox, C., LEBEAU, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, et al
1997; 89 (6): 2079-2088
- **Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells** *BLOOD*
Rajapaksa, R., Ginzton, N., Rott, L. S., Greenberg, P. L.
1996; 88 (11): 4275-4287
- **GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation** *BONE MARROW TRANSPLANTATION*
Greenberg, P., Advani, R., Keating, A., Gulati, S. C., Nimer, S., Champlin, R., Karanes, C., Gorin, N. C., Powles, R. L., Smith, A., Lamborn, K., Cuffie, C.
1996; 18 (6): 1057-1064
- **Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy** *BLOOD*
Negrin, R. S., Stein, R., Doherty, K., Cornwell, J., Vardiman, J., Krantz, S., Greenberg, P. L.
1996; 87 (10): 4076-4081
- **Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes** *SEMINARS IN HEMATOLOGY*
Greenberg, P. L.
1996; 33 (2): 163-175
- **Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human G-CSF plus erythropoietin: Evidence for in vivo synergy** *Blood*
Negrin RS, Stein R, Doherty K, Cromwell J, Vardiman J, Krantz S, Greenberg PL
1996; 87: 4076-4081
- **ENRICHMENT OF BONE-MARROW AND BLOOD PROGENITOR (CD34(+)) CELLS BY DENSITY GRADIENTS WITH SUFFICIENT YIELDS FOR TRANSPLANTATION** *EXPERIMENTAL HEMATOLOGY*
Schriber, J. R., DEJBAKHSHJONES, S., KUSNIERZGLAZ, C. R., Ginzton, N., Still, B., Negrin, R. S., Greenberg, P., Strober, S.
1995; 23 (9): 1024-1029
- **MODULATION OF APOPTOSIS IN HUMAN MYELOID LEUKEMIC-CELLS BY GM-CSF** *EXPERIMENTAL HEMATOLOGY*
Han, J. H., Gileadi, C., Rajapaksa, R., Kosek, J., Greenberg, P. L.
1995; 23 (3): 265-272
- **THE ROLE OF HEMATOPOIETIC GROWTH-FACTORS IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES** *International Symposium on Current Problems of Childhood Pannmyelopathies - Focus on Myelodysplastic Syndrome*
Greenberg, P.
MINISTERSTVO ZDRAVOOKHRANENIYA.1995: 12-13
- **EFFECTS OF GRANULOCYTE-COLONY-STIMULATING FACTOR THERAPY ON IN-VITRO HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES** *LEUKEMIA*
Nagler, A., MacKichan, M. L., Negrin, R. S., Donlon, T., Greenberg, P. L.
1995; 9 (1): 30-39
- **EXPRESSION OF EVII IN MYELODYSPLASTIC SYNDROMES AND OTHER HEMATOLOGIC MALIGNANCIES WITHOUT 3Q26 TRANSLOCATIONS** *BLOOD*
Russell, M., List, A., Greenberg, P., Woodward, S., Glinsmann, B., Parganas, E., Ihle, J., Taetle, R.
1994; 84 (4): 1243-1248
- **MUTATIONS IN THE RAS PROTOONCOGENES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES** *LEUKEMIA*
Neubauer, A., Greenberg, P., Negrin, R., Ginzton, N., Liu, E.
1994; 8 (4): 638-641
- **PHASE-III RANDOMIZED MULTICENTER TRIAL OF G-CSF VS OBSERVATION FOR MYELODYSPLASTIC SYNDROMES (MDS)**
Greenberg, P., Taylor, K., Larson, R., Koeffler, P., Negrin, R., Saba, H., Ganser, A., Jakubowski, A., Gabrilove, J., Mufti, G., Cruz, J., Hammond, W., Broudy, et al
AMER SOC HEMATOLOGY.1993: A196-A196
- **TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN COMBINATION WITH ERYTHROPOIETIN** *BLOOD*
Negrin, R. S., Stein, R., Vardiman, J., Doherty, K., Cornwell, J., Krantz, S., Greenberg, P. L.

- 1993; 82 (3): 737-743
- **T-CELL SUBSETS AND SUPPRESSOR CELLS IN HUMAN BONE-MARROW BLOOD**
SCHMIDTWOLF, I. G., DEJBAKSHJONES, S., Ginzton, N., Greenberg, P., Strober, S.
1992; 80 (12): 3242-3250
 - **INVITRO MARROW CULTURE STUDIES IN THE MYELOYDYSPLASTIC SYNDROMES SEMINARS IN ONCOLOGY**
Greenberg, P. L.
1992; 19 (1): 34-46
 - **TREATMENT OF MYELOYDYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS SEMINARS IN ONCOLOGY**
Greenberg, P. L.
1992; 19 (1): 106-114
 - **Programmed cell death (apoptosis) as a mechanism for regulating haematopoietic cell population size Focus on Growth Factors**
Greenberg, P. L.
1992; 3 (2): 1-3
 - **TREATMENT OF MYELOYDYSPLASTIC SYNDROMES BLOOD REVIEWS**
Greenberg, P. L.
1991; 5 (1): 42-50
 - **EFFECTS OF INSULIN-LIKE GROWTH-FACTORS ON HEMATOPOIESIS BLOOD CELLS**
Greenberg, P. L.
1991; 17 (2): 344-346
 - **GRANULOCYTE-MONOCYTE AND GRANULOCYTE-COLONY STIMULATING FACTORS IN MYELOYDYSPLASTIC SYNDROMES LEUKEMIA & LYMPHOMA**
Nagler, A., Greenberg, P. L.
1991; 5 (4): 219-230
 - **FUNCTIONAL INTERACTIONS BETWEEN COLONY-STIMULATING FACTORS AND THE INSULIN FAMILY HORMONES FOR HUMAN MYELOID LEUKEMIC-CELLS CANCER RESEARCH**
Oksenberg, D., DIECKMANN, B. S., Greenberg, P. L.
1990; 50 (20): 6471-6477
 - **IMPACT OF MARROW CYTOGENETICS AND MORPHOLOGY ON INVITRO HEMATOPOIESIS IN THE MYELOYDYSPLASTIC SYNDROMES - COMPARISON BETWEEN RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (CSF) AND GRANULOCYTE-MONOCYTE CSF BLOOD**
Nagler, A., Binet, C., MacKichan, M. L., Negrin, R., Bangs, C., Donlon, T., Greenberg, P.
1990; 76 (7): 1299-1307
 - **EFFECTS OF CSFS IN PRELEUKEMIA 3RD INTERNATIONAL SYMP ON MINIMAL RESIDUAL DISEASE IN ACUTE LEUKEMIA**
Greenberg, P. L., Negrin, R., Nagler, A.
STOCKTON PRESS.1990: 121-126
 - **MAINTENANCE TREATMENT OF PATIENTS WITH MYELOYDYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR BLOOD**
Negrin, R. S., HAEUBER, D. H., Nagler, A., Kobayashi, Y., Sklar, J., Donlon, T., Vincent, M., Greenberg, P. L.
1990; 76 (1): 36-43
 - **BONE-MARROW CELL MODULATION AND INHIBITION OF MYELOPOIESIS BY LARGE GRANULAR LYMPHOCYTES AND NATURAL-KILLER-CELLS INTERNATIONAL JOURNAL OF CELL CLONING**
Nagler, A., Greenberg, P. L.
1990; 8 (3): 171-183
 - **EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR ON INVITRO HEMATOPOIESIS IN THE MYELOYDYSPLASTIC SYNDROMES LEUKEMIA**
Nagler, A., Ginzton, N., Negrin, R., Bang, D., Donlon, T., Greenberg, P.
1990; 4 (3): 193-202

- **HEMATOPOIETIC PROGENITOR-CELL EXPRESSION OF THE H-CAM (CD44) HOMING-ASSOCIATED ADHESION MOLECULE** *BLOOD*
LEWINSOHN, D. M., Nagler, A., Ginzton, N., Greenberg, P., BUTCHER, E. C.
1990; 75 (3): 589-595
- **EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR** *2ND INTERNATIONAL CONF ON BLOOD CELL GROWTH FACTORS : THEIR BIOLOGY AND CLINICAL APPLICATIONS*
Greenberg, P., Negrin, R., Nagler, A., Vincent, M., Donlon, T.
ALPHAMED PRESS.1990: 293-302
- **TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR - CLINICAL AND MARROW HEMATOPOIETIC RESPONSES** *SYMP ON HEMATOPOIESIS*
Greenberg, P., Negrin, R., Nagler, A., Souza, L.
WILEY-LISS, INC.1990: 229-236
- **TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR - A PHASE I-II TRIAL** *ANNALS OF INTERNAL MEDICINE*
Negrin, R. S., HAEUBER, D. H., Nagler, A., Olds, L. C., Donlon, T., SOUZA, L. M., Greenberg, P. L.
1989; 110 (12): 976-984
- **THE EFFECTS OF RECOMBINANT INTERLEUKIN-2-ACTIVATED NATURAL-KILLER CELLS ON AUTOLOGOUS PERIPHERAL-BLOOD HEMATOPOIETIC PROGENITORS** *JOURNAL OF EXPERIMENTAL MEDICINE*
Nagler, A., Greenberg, P. L., Lanier, L. L., Phillips, J. H.
1988; 168 (1): 47-54
- **SELECTIVE GENERATION OF ERYTHROID BURST PROMOTING ACTIVITY BY RECOMBINANT INTERLEUKIN-2 STIMULATED HUMAN LYMPHOCYTES-T AND NATURAL-KILLER CELLS** *BLOOD*
Skettino, S., Phillips, J., Lanier, L., Nagler, A., Greenberg, P.
1988; 71 (4): 907-914
- **RECEPTOR-BINDING AND MITOGENIC EFFECTS OF INSULIN AND INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II FOR HUMAN MYELOID LEUKEMIC-CELLS** *JOURNAL OF CELLULAR PHYSIOLOGY*
PEPE, M. G., Ginzton, N. H., Lee, P. D., Hintz, R. L., Greenberg, P. L.
1987; 133 (2): 219-227
- **BIOLOGIC NATURE OF THE MYELODYSPLASTIC SYNDROMES** *ACTA HAEMATOLOGICA*
Greenberg, P. L.
1987; 78: 94-99
- **BIOLOGIC ABNORMALITIES IN THE MYELODYSPLASTIC SYNDROMES AND MYELOPROLIFERATIVE DISORDERS** *ACTA HAEMATOLOGICA JAPONICA*
Greenberg, P. L.
1986; 49 (8): 1509-1527
- **CHARACTERIZATION OF THE INVITRO STROMAL MICROENVIRONMENT OF HUMAN-BONE MARROW** *INTERNATIONAL JOURNAL OF CELL CLONING*
Strobel, E. S., GAY, R. E., Greenberg, P. L.
1986; 4 (5): 341-356
- **13-CIS RETINOIC ACID TREATMENT FOR MYELODYSPLASTIC SYNDROMES** *JOURNAL OF CLINICAL ONCOLOGY*
Picozzi, V. J., SWANSON, G. F., Morgan, R., Hecht, F., Greenberg, P. L.
1986; 4 (4): 589-595
- **ABNORMAL INVITRO CLONAL GROWTH-PATTERNS IN THE MYELODYSPLASTIC SYNDROMES AND OTHER HEMATOLOGIC MALIGNANCIES - RESPONSES TO RETINOIC ACID AND VITAMIN-D** *ACTA HAEMATOLOGICA JAPONICA*
Greenberg, P.
1986; 49 (2): 181-181
- **RESPONSES OF HEMATOPOIETIC PRECURSORS TO 13-CIS RETINOIC ACID AND 1,25 DIHYDROXYVITAMIN-D3 IN THE MYELODYSPLASTIC SYNDROMES** *BLOOD*
Swanson, G., Picozzi, V., Morgan, R., Hecht, F., Greenberg, P.

1986; 67 (4): 1154-1161

- **CORRELATIVE PATTERNS OF LEUKOCYTE COUNTS AT PRESENTATION AND RELAPSE IN ACUTE MYELOGENOUS LEUKEMIA** *ACTA HAEMATOLOGICA*
Schwartz, R. S., MacKintosh, F. R., Greenberg, P. L.
1986; 75 (2): 79-82
- **HUMAN SPLEEN-CELL GENERATION OF FACTORS STIMULATING HUMAN PLURIPOTENT STEM-CELL, ERYTHROID, AND MYELOID PROGENITOR-CELL GROWTH** *BLOOD*
Fabian, I., Douer, D., Levitt, L., Kletter, Y., Greenberg, P. L.
1985; 65 (4): 990-996
- **LITHIUM TREATMENT IN ADULTS WITH ACUTE MYELOID-LEUKEMIA RECEIVING CHEMOTHERAPY** *MEDICAL AND PEDIATRIC ONCOLOGY*
Horns, R. C., Schrier, S. L., Greenberg, P. L.
1984; 12 (3): 169-172
- **MULTIVARIATE-ANALYSIS OF FACTORS ASSOCIATED WITH OUTCOME OF TREATMENT FOR ADULTS WITH ACUTE MYELOGENOUS LEUKEMIA** *CANCER*
Schwartz, R. S., MacKintosh, F. R., Halpern, J., Schrier, S. L., Greenberg, P. L.
1984; 54 (8): 1672-1681
- **MULTIVARIATE-ANALYSIS OF FACTORS ASSOCIATED WITH INVASIVE FUNGAL DISEASE DURING REMISSION INDUCTION THERAPY FOR ACUTE MYELOGENOUS LEUKEMIA** *CANCER*
Schwartz, R. S., MacKintosh, F. R., Schrier, S. L., Greenberg, P. L.
1984; 53 (3): 411-419
- **MURINE GRANULOPOIESIS AFTER FRACTIONATED TOTAL LYMPHOID IRRADIATION AND ALLOGENEIC BONE-MARROW TRANSPLANTATION** *EXPERIMENTAL HEMATOLOGY*
Feiner, R. H., Strober, S., Greenberg, P. L.
1983; 11 (5): 410-417
- **PURE WHITE-CELL APLASIA - ANTIBODY-MEDIATED AUTOIMMUNE INHIBITION OF GRANULOPOIESIS** *NEW ENGLAND JOURNAL OF MEDICINE*
Levitt, L. J., Ries, C. A., Greenberg, P. L.
1983; 308 (19): 1141-1146
- **RESPONSE OF AGRANULOCYTOSIS TO PROLONGED ANTI-THYMOCYTE GLOBULIN THERAPY** *JOURNAL OF PEDIATRICS*
CHUDWIN, D. S., Cowan, M. J., Greenberg, P. L., Wara, D. W., Ammann, A. J.
1983; 103 (2): 223-227
- **THE SMOLDERING MYELOID LEUKEMIC STATES - CLINICAL AND BIOLOGIC FEATURES** *BLOOD*
Greenberg, P. L.
1983; 61 (6): 1035-1044
- **INDUCTION OF HUMAN HEMATOPOIETIC STEM-CELL (CFU-GEMM) GROWTH BY FACTORS RELEASED FROM MITOGEN-STIMULATED SPLEEN-CELLS**
Fabian, I., Levitt, L., Greenberg, P.
ELSEVIER SCIENCE INC.1982: 167-167
- **ROLE OF INTRACELLULAR DEGRADATION OF EPIDERMAL GROWTH-FACTOR IN MITOGENESIS** *EXPERIMENTAL CELL RESEARCH*
Greenberg, P. L., ROZENGURT, E.
1982; 142 (1): 111-117
- **SPLenic GRANULOCYTOPOIESIS AND PRODUCTION OF COLONY-STIMULATING ACTIVITY IN LYMPHOMA AND LEUKEMIA** *BLOOD*
Greenberg, P. L., STEED, S. M.
1981; 57 (1): 119-129
- **STROMAL COLONY-STIMULATING ACTIVITY PRODUCTION AND MYELOID COLONY-FORMING CELLS IN HUMAN HEMATOPOIETIC AND NON-HEMATOPOIETIC BONE-MARROW** *BLOOD*
Schwartz, R. S., Greenberg, P. L.

1981; 57 (4): 771-780

- **CHARACTERIZATION OF ANTIGENIC DETERMINANTS ON HUMAN MYELOID COLONY-FORMING CELLS WITH MONOCLONAL-ANTIBODIES** *EXPERIMENTAL HEMATOLOGY*
Greenberg, P., Grossman, M., Charron, D., Levy, R.
1981; 9 (7): 781-787
- **THE CHRONIC IDIOPATHIC NEUTROPENIA SYNDROME - CORRELATION OF CLINICAL-FEATURES WITH INVITRO PARAMETERS OF GRANULOCYTOPOIESIS** *BLOOD*
Greenberg, P. L., MARA, B., Steed, S., Boxer, L.
1980; 55 (6): 915-921
- **CLINICAL RELEVANCE OF INVITRO STUDY OF GRANULOCYTOPOIESIS** *SCANDINAVIAN JOURNAL OF HAEMATOLOGY*
Greenberg, P. L.
1980; 25 (5): 369-381
- **SUB-ACUTE MYELOID-LEUKEMIA - CLINICAL REVIEW** *AMERICAN JOURNAL OF MEDICINE*
Cohen, J. R., CREGER, W. P., Greenberg, P. L., Schrier, S. L.
1979; 66 (6): 959-966
- **Intramedullary influences on in vitro granulopoiesis in human acute myeloid leukemia.** *Haematology and blood transfusion*
Greenberg, P., MARA, B.
1979; 23: 199-204
- **PRELEUKEMIC SYNDROME - CORRELATION OF INVITRO PARAMETERS OF GRANULOPOIESIS WITH CLINICAL-FEATURES** *AMERICAN JOURNAL OF MEDICINE*
Greenberg, P. L., MARA, B.
1979; 66 (6): 951-958
- **MARROW ADHERENT CELL COLONY-STIMULATING ACTIVITY PRODUCTION IN ACUTE MYELOID-LEUKEMIA** *BLOOD*
Greenberg, P. L., MARA, B., Heller, P.
1978; 52 (2): 362-378
- **REMISSION OF ACUTE MYELOGENOUS LEUKEMIA COMPLICATING WALDENSTROM MACROGLOBULINEMIA** *WESTERN JOURNAL OF MEDICINE*
EFFRON, M. K., Rosenbaum, J., Greenberg, P. L.
1978; 129 (4): 337-339
- **REMISSION MAINTENANCE THERAPY IN ACUTE MYELOGENOUS LEUKEMIA** *WESTERN JOURNAL OF MEDICINE*
Embury, S. H., Elias, L., Heller, P. H., HOOD, C. E., Greenberg, P. L., Schrier, S. L.
1977; 126 (4): 267-272
- **DENSITY DISTRIBUTION PATTERNS OF MARROW COLONY-FORMING CELLS DURING REMISSION OF ACUTE MYELOGENOUS LEUKEMIA** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Heller, P., Greenberg, P.
1977; 59 (2): 313-316
- **CYTOTOXIC EFFECTS OF INTERFERON INVITRO ON GRANULOCYTIC PROGENITOR CELLS** *CANCER RESEARCH*
Greenberg, P. L., MOSNY, S. A.
1977; 37 (6): 1794-1799
- **DIVERGENT PATTERNS OF MARROW CELL-SUSPENSION CULTURE GROWTH IN MYELOID LEUKEMIAS - CORRELATION OF INVITRO FINDINGS WITH CLINICAL FEATURES** *BLOOD*
Elias, L., Greenberg, P.
1977; 50 (2): 263-274
- **MYELOPROLIFERATIVE DISORDERS - CORRELATION BETWEEN CLINICAL EVOLUTION AND ALTERATIONS OF GRANULOPOIESIS** *AMERICAN JOURNAL OF MEDICINE*
Greenberg, P., MARA, B., Bax, I., BROSSSEL, R., Schrier, S.
1976; 61 (6): 878-891

- **ALTERATION OF COLONY-STIMULATING FACTOR OUTPUT, ENDOTOXEMIA, AND GRANULOPOIESIS IN CYCLIC NEUTROPENIA** *AMERICAN JOURNAL OF HEMATOLOGY*
Greenberg, P. L., Bax, I., Levin, J., Andrews, T. M.
1976; 1 (4): 375-385
- **CYTOTOXIC EFFECTS OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE AND 6-THIOGUANINE INVITRO ON GRANULOCYTIC PROGENITOR CELLS** *CANCER RESEARCH*
Greenberg, P. L., VANKERSEN, I., MOSNY, S.
1976; 36 (12): 4412-4417
- **Cytotoxic effects of cytosine arabinoside and 6-thioguanine in vitro on granulocytic progenitor cells** *Cancer Res*
Greenberg, P. L., VanKersen, I., Mosny, S.
1976: 4412-4417
- **ALTERATIONS OF GRANULOPOIESIS FOLLOWING CHEMOTHERAPY** *BLOOD*
GREENBER, P., Bax, I., MARA, B., Schrier, S.
1974; 44 (3): 375-383
- **CLINICAL UTILITY OF INVITRO EVALUATION OF GRANULOPOIESIS** *ANNUAL REVIEW OF MEDICINE*
GREENBER, P. L., Schrier, S. L.
1974; 25: 269-278
- **GRANULOPOIESIS IN NEUTROPENIC DISORDERS** *BLOOD*
GREENBER, P. L., Schrier, S. L.
1973; 41 (6): 753-769
- **The anemia of chronic disorders due to renal cell carcinoma: ferrokinetic and morphologic documentation of its surgical correction.** *The American journal of the medical sciences*
Greenberg, P. L., CREGER, W. P.
1971; 261 (5): 265-269
- **Granulopoiesis in acute myeloid leukemia and preleukemia** *New Engl J Med*
Greenberg PL, Nichols WC, Schrier SL
1971; 284: 1225-1232
- **GRANULOPOIESIS IN ACUTE MYELOID LEUKEMIA AND PRELEUKEMIA** *NEW ENGLAND JOURNAL OF MEDICINE*
Greenberg, P. L., Nichols, W. C., Schrier, S. L.
1971; 284 (22): 1225-?